Xingyu Lin

Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.

Xi-Ping Huang, N. Huang, Yu Zhou, 2016, Journal of medicinal chemistry.

Identifying multiple-target ligands via computational chemogenomics approaches.

Niu Huang, Zongru Guo, N. Huang, 2012, Current topics in medicinal chemistry.

Targeting SREBP-1-Mediated Lipogenesis as Potential Strategies for Cancer

Xingyu Lin, Guan Wang, Qiushi Zhao, 2022, Frontiers in Oncology.

Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).

Benjamin D. Sellers, Rohan V Mendonca, G. Hatzivassiliou, 2018, ACS medicinal chemistry letters.

Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.

Niu Huang, Bryan L Roth, Xi-Ping Huang, 2012, Journal of medicinal chemistry.

Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing Kinase.

Jianwen A. Feng, P. McEwan, Lawren C. Wu, 2018, Journal of medicinal chemistry.

A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma

Zhanghua Wu, Liwei Zhang, Xingyu Lin, 2023, Journal of Neuro-Oncology.